文献速递免疫规划卫生政策与健康促进慢病防控与筛查

约旦人乳头瘤病毒疫苗接种的成本效果:一项建模研究

Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study.
PubMed 文献 · Vaccine · 2026-05-02

该建模研究评估约旦12岁女孩单剂HPV疫苗接种规划(2026—2035年)的终生成本与健康后果,以政府视角计算每避免一个DALY的成本(2023年美元)。结果显示Cecolin®在97%的概率分析中具有成本节约性,Cervarix™健康获益更大但需额外成本,Gardasil®因成本更高且健康获益不更优而被排除。

要点

  • 单剂Cecolin®接种可预防超半数终生宫颈癌病例和死亡,且很可能成本节约。
  • Cervarix™健康获益大于Cecolin®,但每避免一个额外DALY需花费2025美元。
  • Gardasil®因成本更高且健康获益不优于其他产品而被排除。

核心结论

  • 单剂Cecolin®可预防约旦超半数终生宫颈癌病例和死亡,且很可能成本节约。
  • Cervarix™可能比Cecolin®更具影响力,但取决于交叉保护假设。

研究设计与样本

  • 建模研究,评估2026—2035年约旦12岁女孩单剂HPV疫苗接种规划的终生成本与后果。
  • 主要结局为政府视角下每避免一个DALY的成本(2023年美元),对照为无HPV疫苗接种且筛查服务不变的情景。

主要发现

  • 十年接种可在接种女孩终生中预防至少2200例宫颈癌和1200例死亡(降幅超50%)。
  • 相比Cecolin®,Cervarix™每避免一个额外DALY需花费2025美元,在0.7倍人均GDP阈值下具成本效果的概率为100%。
  • Gardasil®(每剂13.50美元)因成本更高且健康获益等效或更低而被排除。

关键数值与推荐

  • 成本效果阈值设定为0.7倍全国人均GDP。
  • Cecolin®每剂2.90美元,Cervarix™每剂10.25美元,Gardasil®每剂13.50美元。

临床怎么用

  • 约旦可优先考虑引入单剂Cecolin®HPV疫苗接种规划,因其很可能成本节约。
  • 若追求更大健康获益且预算允许,Cervarix™可作为备选,但需考虑交叉保护假设。
  • 需多部门持续参与和捐助方合作以确保可持续纳入国家免疫规划。

局限性

  • 结果基于建模假设,Cervarix™的相对影响力取决于交叉保护假设。
  • 研究未报告长期规划外的实际实施可行性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer remains a preventable but persistent public health challenge. Human papillomavirus (HPV) vaccination offers an effective strategy to reduce cervical cancer incidence and mortality, but there is limited evidence on its potential impact and cost-effectiveness in Jordan. METHODS: We modelled the lifetime costs and consequences of a single-dose HPV vaccination program (2026-2035) for girls aged 12 years in Jordan. The primary outcome measure was the cost (2023 USD) per disability-adjusted life year (DALY) averted, from a government perspective. The comparator was a scenario with no HPV vaccination and no change in existing cervical cancer screening services. We calculated vaccine program costs, and cervical cancer cases, deaths, DALYs and healthcare costs averted by three alternative HPV vaccine products (Cecolin®, Cervarix™ and Gardasil®). We ran deterministic and probabilistic uncertainty analyses and estimated the probability that the vaccine would be cost-effective at a threshold set at 0.7 times the national gross domestic product (GDP) per capita. RESULTS: A decade of vaccination in Jordan could prevent at least 2200 cervical cancer cases and 1200 deaths (a reduction of over 50%) over the lifetimes of the vaccinated girls. The program costs associated with introducing Cecolin® ($2.90 per dose) were $9.2 million, but this was offset by around $14.6 million in treatment cost savings (Cecolin® was cost-saving in 97% of the probabilistic runs). Cervarix™ ($10.25 per dose) was estimated to cost $16.2 million but had greater health benefits than Cecolin® (68% versus 55% impact). Compared to Cecolin® each additional DALY averted by Cervarix™ would cost $2025. Cervarix™ had a 100% probability of being cost-effective at a threshold of 0.7 times the national GDP per capita) when compared directly to Cecolin®. Gardasil® ($13.50 per dose) was dominated/removed because it generated equivalent or lower health benefits to the other products at higher cost. The results were robust to changes in key input parameters. CONCLUSION: A single dose of Cecolin® could prevent more than half of the expected lifetime cervical cancer cases and deaths in Jordan and is very likely to be cost saving. Cervarix™ may be more impactful than Cecolin® but this depends on cross-protection assumptions. Continued multi-sectoral engagement and donor collaboration will be essential to ensure sustainable integration into the national immunization programme.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mousa AAB, Thneibat FM, Al-Hamdan Z, et al. Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study. Vaccine. 2026. PMID: 42070373. doi:10.1016/j.vaccine.2026.128640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。